Mesothelioma Cancer Centers
University of California San Diego (UCSD) Health
Doctors Affiliated with this Treatment Facility
The Moores Cancer Center, located on the UC San Diego Health Campus and also known as University of California San Diego Cancer Center, is a National Cancer Institute (NCI) designated Comprehensive Cancer Center. It is the only cancer center to receive the designation in the San Diego area. The center employs 14 cancer teams that work together in specialty and subspecialty groups to treat patients with both common and rarer cancers, like mesothelioma. These multidisciplinary teams treat not only the patient’s cancer, but also provides holistic support for the patient, their family and caregivers. Support services offered include support groups, nutrition services and other emotional support services.
Mesothelioma patients receiving care at the Moores Cancer Center benefit from their Rare Tumor Clinic, which emphasizes genomically targeted treatments with immunotherapy. The center also offers a wide array of clinical trials, which enables patients to receive cutting edge care. The Moores Cancer Center frequently offers over 100 clinical trials at one time, allowing patients easier access to emerging therapies. One such cutting edge therapy offered at the center is heated intraperitoneal chemotherapy or HIPEC, a treatment that has proven to lead to improved survival rates for peritoneal mesothelioma. The surgeons at Moores are some of the most experienced at the cytoreductive/HIPEC surgery combination, performing around three procedures each week.
In addition to HIPEC, the physicians at the Moores Cancer Center are well versed in other procedures commonly used for mesothelioma treatment, including thoracoscopy and the standard treatment modalities: radiation, chemotherapy and general surgery.
- Clinical trials
- Cytoreductive surgery
- Heated intraperitoneal chemotherapy (HIPEC)
- Palliative care
- Peritoneal mesothelioma
- Personalized cancer therapy
- Radiation oncology
- American College of Surgeons Commission on Cancer (CoC) Accreditation
- Cancer Center ranked as High Performing according to U.S. News & World Report Best Hospitals report
- Included in the 100 Hospitals and Health Systems with Great Oncology Programs report by Becker’s Hospital Review
- NCI-designated Comprehensive Cancer Center
Mesothelioma Clinical Trials at University of California San Diego (UCSD) Health
The following clinical trials are in progress or actively recruiting participants at University of California San Diego (UCSD) Health:
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma Last Updated: July 18, 2019 Status: Recruiting
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Conditions: Mesothelin Positive; Pleural Malignant Mesothelioma Last Updated: July 17, 2019 Status: Recruiting
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma; Pleural Mesothelioma Last Updated: June 17, 2019 Status: Active, not recruiting
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Conditions: Advanced Solid Tumors Cancer Last Updated: June 6, 2019 Status: Recruiting
Conditions: Advanced Solid Tumors Last Updated: March 13, 2019 Status: Recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
UC San Diego Health. Cancer Services. Medical Services.
UC San Diego Health. Cancers Treated with HIPEC. Peritoneal Surface Malignancies and HIPEC.
UC San Diego Health. Cancer Treatment Programs. Cancer Services.
UC San Diego Health. Moores Cancer Center - La Jolla. Locations.
UC San Diego Health. Patient Resources. Cancer Services.
UC San Diego Health. Quality Cancer Care: Awards and Reports. About Moores Cancer Center.
UC San Diego Health. Rare Tumor Clinic. Personalized Therapy.